Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. The Ultimate Stock-Pickers’ Top 10 Dividend Stocks

      Headlines

      Tue, 16 Sep 2014

      with Mattel MAT, Intel INTC, Novartis NVS , and Cisco CSCO making way for ..... see Johnson & Johnson JNJ and Novartis making the list, with Wells Fargo ..... 25.16 0.97 2.9 Medium 9 1 Novartis * NVS 3 Wide 93.76 1.03 2.9 Low

    2. IXJ iShares Global Healthcare ETF Analysis, Report, Research, 5 Star Rating – Morningstar

      ETF Reports

      Mon, 15 Sep 2014

      suitable satellite holding. This fund holds major U.S. health-care companies and mega-cap foreign firms such as Novartis NVS , Roche, and Sanofi SNY, with foreign firms making up about 37% of the fund's assets. We would caution investors

    3. Vectura Group Following A Familiar Path

      Headlines

      Sat, 13 Sep 2014

      and manufacture of inhaled drugs and devices to administer these drugs. Vectura boasts a key partnership with Novartis (NYSE: NVS ) for potential blockbuster Ultibro as well as Seebri, as well as a diverse pipeline of generic and branded respiratory

    4. Biosimilars on the horizon in the U.S.

      Headlines

      Fri, 12 Sep 2014

      1.3% ). There are 14 biotech meds being targeted by pharmaceutical firms who want to sell cheaper versions. Novartis ( NVS -0.7% ) submitted the first filing with the FDA in July for its version of Amgen's ( AMGN -0.9% ) Neupogen

    5. Novartis LCZ696: 'New Wonder Drug' OR 'Old Paradigm With Reduced Side Effects'

      Headlines

      Fri, 12 Sep 2014

      Again, headline results for Novartis ' new heart failure (HF) drug ..... new drug, LCZ696. The HYPE FOR NOVARTIS ( NVS ) SERELAXIN Chicago Tribune - 6 ..... an article with the headline, Novartis heart failure drug cuts death by

    6. How Much Is Novartis's New Heart Failure Medicine Worth?

      Headlines

      Thu, 11 Sep 2014

      By Kanak Kanti De : Swiss drug maker Novartis AG (NYSE: NVS ) recently reported strong data from the PARADIGM ..... blockbuster drug. But how much is it worth? Robust Data Novartis recently revealed data from PARADIGM-HF trial for

    7. New Morningstar Analyst Report for Amgen Inc

      Stock Reports

      Thu, 11 Sep 2014

      several of Amgen's newer products have entered highly competitive markets. Prolia competes with established drugs such as Novartis ' Reclast and cheaper generic bisphosphonates; Vectibix competes with Roche's Avastin and Eli Lilly and Bristol-Myers

    8. New Morningstar Analyst Report for Baxter International Inc

      Stock Reports

      Thu, 11 Sep 2014

      of medical products, spent 14 years at Lilly, and Ludwig Hantson, head of BioScience, spent more than 20 years at Novartis and Johnson & Johnson. Following the biopharmaceutical spin-off in 2015, Parkinson will lead the new Baxter while

    9. PDL BioPharma forecasts 65% revenue increase for Q3

      Headlines

      Tue, 9 Sep 2014

      from the Queen et al. licenses should come in at ~$124M (+29% yoy). Guidance is net of the estimated payment from Novartis due under the February 2011 settlement. Post your comment!

    10. Riding Merck: The Conservative Aggressive Pharmaceutical Stock Of The Year

      Headlines

      Tue, 9 Sep 2014

      GlaxoSmithKline (NYSE: GSK ) is down 10%, Pfizer (NYSE: PFE ) is down 3.5%, J&J (NYSE: JNJ ) is up 13%, Novartis (NYSE: NVS ) is up 16%, and MRK is up a whopping 22% . Big Pharma Performance -- 2014 YTD (Click to enlarge) Source

    « Prev12345Next »
    Content Partners